S Zorzet Selected Research

imidazolium- bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III) (NAMI-A)

4/2006	Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
2/2002	Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
5/2001	Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
1/2001	Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma.
12/2000	Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
9/2000	Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
9/2000	Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
4/2000	Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S Zorzet Research Topics

Disease

9	Neoplasms (Cancer) 07/2015 - 01/2000
7	Neoplasm Metastasis (Metastasis) 04/2006 - 01/2000
6	Carcinoma (Carcinomatosis) 02/2002 - 01/2000
3	Adenocarcinoma 05/2001 - 09/2000
3	Lewis Lung Carcinoma 12/2000 - 01/2000
1	Endometriosis 01/2015
1	Phototoxic Dermatitis (Phototoxicity) 01/2012
1	Acute Promyelocytic Leukemia 05/2006
1	Melanoma (Melanoma, Malignant) 04/2006
1	Experimental Melanoma 04/2006

Drug/Important Bio-Agent (IBA)

8	imidazolium- bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III) (NAMI-A)IBA 04/2006 - 04/2000
7	RutheniumIBA 04/2006 - 04/2000
2	Cysteine (L-Cysteine)FDA Link 01/2015 - 02/2002
2	LigandsIBA 01/2009 - 02/2002
2	dichlorotetrakis(dimethyl sulfoxide)ruthenium II (trans-Ru)IBA 12/2000 - 09/2000
1	Pharmaceutical PreparationsIBA 07/2015
1	Complement System Proteins (Complement)IBA 02/2015
1	AntibodiesIBA 02/2015
1	Bispecific AntibodiesIBA 02/2015
1	AntigensIBA 02/2015
1	Bromelains (Bromelain)IBA 01/2015
1	Thioctic Acid (Lipoic Acid)IBA 01/2015
1	Therapeutic UsesIBA 01/2015
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2012
1	Death Domain ReceptorsIBA 01/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2009
1	EstersIBA 05/2006
1	Hyaluronic Acid (Hyaluronan)IBA 05/2006
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2006
1	Fibronectins (Fibronectin)IBA 04/2006
1	Lysine (L-Lysine)FDA Link 04/2006
1	Actins (F Actin)IBA 04/2006
1	GelatinasesIBA 04/2006
1	Glutathione (Reduced Glutathione)IBA 02/2002
1	SolutionsIBA 02/2002
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 02/2002
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 02/2002
1	SodiumIBA 12/2000
1	matrigelIBA 12/2000
1	PlasticsIBA 09/2000
1	Antineoplastic Agents (Antineoplastics)IBA 04/2000
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2000
1	Lomustine (CCNU)FDA Link 01/2000
1	Dacarbazine (DIC)FDA LinkGeneric 01/2000

Therapy/Procedure

2	Immunotherapy 02/2015 - 09/2000
1	Therapeutics 05/2006